TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00193414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500mg/m2 IV over 10 min, Day 1, prior to gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1500mg/m2, 30min IV
Study: NCT03069235

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family member / peer support
Description: supplemental individualized counselling

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family member / peer support
Description: supplemental individualized counselling

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced intervention with counselor support
Description: hands on EBF demonstrations

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard of care
Description: one on one and in-group counselling
Study: NCT04244617

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iCBT with addition of peer-support
Description: Peer-supporters and participants, as well as psychologists and participants, interact in the treatment program via asynchronous secure messages. Peer-supporters are able to give support and feedback on exercises. A reconciliation call via telephone is entered into the middle of the treatment and a follow-up call after completion of treatment conducted by the peer-support. The interaction between peer-supporters and participants is tracked by the psychologist.
Study: NCT04214574

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Parasagittal oblique technique (Ultrasound)
Description: the probe will be placed in a parasagittal plane to identify the articular processes then the sacrum will be identified. The probe will be moved cephalad in the parasagittal axis until the identification of the target lumbar interspaces L2-L3, L3-L4 or L4-L5. Once the appropriate lumbar interspace is identified, the probe will be tilted 45 degree towards the midline into a parasagittal oblique view. The needle will be inserted in plane from the caudal end of the ultrasound transducer with its tip directed towards the interlaminar space under real-time in-plane US guidance.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paramedian tranverse technique (Ultrasound)
Description: the transducer will be applied in the parasagittal plane, and after identification of the intervertebral level, the probe will be rotated 90 degrees into a transverse orientation and centered on the neuraxial midline in a way to align the beam with the interspinous and interlaminar space and thus to get a paramedian transverse interlaminar view. The needle will be inserted in plane from the lateral end of the ultrasound transducer with its tip directed towards the medial border of the articular process.
Study: NCT00849069

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK2231395A
Description: 3 doses intramuscular injections

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TwinrixTM
Description: 3 doses intramuscular injections
Study: NCT00541567

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ibipinabant
Description: oral, tablet, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibipinabant
Description: oral, tablet, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibipinabant
Description: oral, tablet, once daily
Study: NCT01606410

Intervention type: OTHER
Intervention: IPC
Description: repeated cuff inflation (220 mmhg) around an upper limb for 5 minutes, followed by 5 minutes of reperfusion (repeated 4 times)

Intervention type: OTHER
Intervention: IPC
Description: repeated cuff inflation (220 mmhg) around an upper limb for 5 minutes, followed by 5 minutes of reperfusion (repeated 4 times)
Study: NCT00541567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibipinabant
Description: oral, tablet, once daily
Study: NCT00666211

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational intervention
Description: Participants will be educated on pain management.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: educational intervention
Description: Participants will be educated on pain management.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Titrated pain management
Description: Pain will be Monitored and Medication Titrated

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Participants will be given questionnaires to complete.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire administration
Description: Participants will be given questionnaires to complete.
Study: NCT00577772

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xifaxan
Description: Open-Label Treatment at 400 mg by mouth, 3 times a day, for 7 days; only for those symptomatic and positive SBBO patients.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SmartPill
Description: The SmartPill is a single-use, ingestible capsule that utilizes sensor technology to measure pressure, pH and temperature throughout the entire GI tract. The ACT-1 (SmartPill) GI Monitoring System includes an ingestible capsule, a receiver and video display software.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SmartPill
Description: The SmartPill is a single-use, ingestible capsule that utilizes sensor technology to measure pressure, pH and temperature throughout the entire GI tract. The ACT-1 (SmartPill) GI Monitoring System includes an ingestible capsule, a receiver and video display software.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lactulose hydrogen breath test (H_2BT)
Description: A hydrogen breath test provides information about the digestion of certain sugars or carbohydrates, such as milk sugar (lactose) or fruit sugar (fructose). The test is also used for detecting abnormal growth of bacteria within the small bowel by having the patient ingest lactulose.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lactulose hydrogen breath test (H_2BT)
Description: A hydrogen breath test provides information about the digestion of certain sugars or carbohydrates, such as milk sugar (lactose) or fruit sugar (fructose). The test is also used for detecting abnormal growth of bacteria within the small bowel by having the patient ingest lactulose.
Study: NCT02198729

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Submucosal Dissection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic Mucosal Resection
Study: NCT00975377

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hair clipping
Description: Patients randomized to the hair clipping cohort will be clipped using an Allegiance 4413 hair clipper. Hair removal will occur on the day of surgery by one of the preoperative nursing staff, immediately prior to the scheduled operation.
Study: NCT04257396

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carbon-Fibre Adjustable Reuseable Accessory (CARA)
Description: Breast support device having a carbon-fibre breast cradle for supine patient positioning.
Study: NCT04164368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide combined with R-CHOP
Description: rituximab 375 mg/m2,ivgtt D1 cyclophosphamide 750 mg/m2 iv D2 vincristine 1.4 mg/m2 \[capped at 2.0 mg\], iv D2 doxorubicin 50 mg/m2 iv D2 prednisone 100 mg/m2 per day PO D2-6 Lenalidomide 25mg PO QD D2-11
Study: NCT00003483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antineoplaston therapy (Atengenal + Astugenal)
Description: Adults with a meningioma will receive Antineoplaston therapy (Atengenal + Astugenal).
Study: NCT01722370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Medical air equivalent
Study: NCT01245374

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Norditropin NordiFlex®
Description: Daily administration by a subcutaneous injection (under the skin). Starting dose and frequency will be determined by the physician as part of normal clinical practice
Study: NCT03487965

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low dose Polyphenol
Description: botanical supplement with 25 mg polyphenol

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High dose Polyphenol
Description: botanical supplement with 13 mg polyphenol

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control
Description: inert tablet made to mimic the experimental tablets
Study: NCT02307045

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: Stimulation of nicotinic receptors by varenicline (Champix) 1,0 mg po

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nicotine
Description: Nicotine replacement therapy with transdermal patches and/or chewing gums
Study: NCT01509547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: participants \>55 kg will take varenicline/placebo 0.5 mg once daily for 3 days, titrated to 0.5 mg twice daily for 4 days, titrated to 1 mg twice daily thereafter. Participants ≤55 kg will take varenicline/placebo 0.5 mg once daily for 7 days, titrated to 0.5 mg twice daily thereafter.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: participants \>55 kg will take varenicline/placebo 0.5 mg once daily for 3 days, titrated to 0.5 mg twice daily for 4 days, titrated to 1 mg twice daily thereafter. Participants ≤55 kg will take varenicline/placebo 0.5 mg once daily for 7 days, titrated to 0.5 mg twice daily thereafter.
Study: NCT01935752

Intervention type: OTHER
Group type: OTHER
Intervention: blood samples
Description: blood samples

Intervention type: OTHER
Group type: OTHER
Intervention: blood samples
Description: blood samples

Intervention type: OTHER
Group type: OTHER
Intervention: blood samples
Description: blood samples

Intervention type: OTHER
Group type: OTHER
Intervention: vascular echotracking
Description: endothelial function study and virtual histology study

Intervention type: OTHER
Group type: OTHER
Intervention: vascular echotracking
Description: endothelial function study and virtual histology study

Intervention type: OTHER
Group type: OTHER
Intervention: vascular echotracking
Description: endothelial function study and virtual histology study
Study: NCT02206061

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: School-Based Asthma Care for Teens (SB-ACT)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Directly Observed Therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Asthma Education
Study: NCT01747551

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ziv-aflibercept
Study: NCT03652441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: BV will be administered i.v. at 1.8mg/kg at 3-weekly intervals for up to 16 infusions
Study: NCT02532127

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saliva sampling
Description: Cells will be collected from consenting participants just before and after (30 min and 24 hr) exposure to CBCT, by brushing a swab against the inner cheek, which can be done by the patients themselves. Swab kits are provided together with an envelope for sending the swabs back.
Study: NCT01399918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus and bevacizumab
Description: Cycle length will be defined as 28 days. Treatment will include everolimus 10mg, self administered orally once daily on a continuous schedule (days 1-28), and bevacizumab 10mg/kg, administered intravenously on days 1 and 15 of each cycle. Treatment will be continued until disease progression, major toxicity, or withdrawal from the study for any reason. Dose modification will be permitted based on toxicity. Patients that come off study before 6 months before documented progression/death will be treated as events for the 6 month PFS endpoint.
Study: NCT01731223

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group treatment for insomnia
Description: Experimental: Group treatment of insomnia The intervention is a group treatment based on cognitive and behavioral changing methods. It is including seven sessions during 10 weeks. Each session last for 2 hours with a 20 minutes pause. The intervention includes psycho education about sleep. Methods as relaxation, coping with worry, sleep restriction, stimulus control, sleep hygiene, stress coping strategies, strategies for coping with daytime symptom, identify and reformulate negative and dysfunctional thoughts about sleep, daytime functioning and stress and strategies for reducing hypnotics.
Study: NCT05624671

Intervention type: OTHER
Group type: OTHER
Intervention: bupivacaine,fentanyl
Description: According to our institution protocol, intravenous (iv) hydration will not be given as preload and afterload and vasopressor infusion will not be initiated before spinal anesthesia. After the skin is prepared sterile and local infiltration with 2% lidocaine is done, from L3-L4 OR L4-L5 range on midline with the 16 gauge Tuohy needle and the loss of resistance technique epidural space is identified and then 26 gauge pencil point needle is passed trough the Touhy and the dura will be drilled. After the cerebrospinal fluid (CSF) is seen the fluid containing 5mg isobaric bupivacaine and 15µg fentanyl will be given in 30 seconds to patients. After the spinal needle is removed, the epidural catheter is placed 3-5 cm in the epidural space through Tuohy, and after the catheter is fixated, the patients will be placed in the supine position by placing a height under their right hip with a 15 ° angle.
Study: NCT00737698

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Physiotherapist-supervised exercise course (endurance and resistance exercises) for 2 hours twice a week for 8 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Repetitive magnetic stimulation
Description: Repetitive magnetic stimulation of the intramuscular branches of the femoral nerve for 3 hours twice a week for 8 weeks
Study: NCT00753064

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiscorpion venom serum(AScVS).
Description: AScVS therapy group~If the score is 5 and if the patient belongs to pediatric group(\>12-14): 1 vial AScVS as i.v. slow bolus after test dose If the score is 5 and if the patient is adult: 2 vials of AScVS as i.v. slow bolus after test dose. For injection, 1 vial will be dissolved in 10 ml distilled water and given over a period of 4 to 5 minutes.~According to the scores 1 vial for pediatric and 2 vials for adult patient will be increased as shown below:~Vials of AScVS Composite score Child Adult 5-10 2 4 \> 10-15 3 6 \>15- 21 4 8

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: T.Prazosin
Description: Prazosin therapy Prazosin (30 micrograms/Kg/dose): 500 micrograms for pediatric patient, and 1mg for adult patients) will be given every 3 hourly orally till complete recovery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AScVS + Prazosin
Description: Combination AScVS and Prazosin therapy In this group, AScVS therapy will be given as mentioned in AScVS therapy group and in addition, prazosin(500 micrograms for pediatric patient and 1mg for adult patients,30 micrograms/Kg/dose) every 3 hourly will be given.
Study: NCT01755572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Single cross-over study, 1 arm starting with liraglutide for 3 weeks crossed-over to placebo for 3 weeks, and 1 arm starting with placebo with cross-over to liraglutide for 3 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Liraglutide
Description: Single cross-over study, 1 arm starting with liraglutide for 3 weeks crossed-over to placebo for 3 weeks, and 1 arm starting with placebo with cross-over to liraglutide for 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single cross-over study, 1 arm starting with liraglutide for 3 weeks crossed-over to placebo for 3 weeks, and 1 arm starting with placebo with cross-over to liraglutide for 3 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single cross-over study, 1 arm starting with liraglutide for 3 weeks crossed-over to placebo for 3 weeks, and 1 arm starting with placebo with cross-over to liraglutide for 3 weeks.
Study: NCT00672737

Intervention type: DRUG
Intervention: Remifentanil
Description: Remifentanil was administered as a computer-controlled infusion, targeting two different effect site concentrations, 1 and 2 mcg/mL, in randomized order.

Intervention type: PROCEDURE
Intervention: Cold pain threshold and tolerance
Description: Ice water was used to assess cold-related pain threshold and tolerance, defined as the time that the volunteers could keep their hands in the water before they started feeling pain or this feeling becomes unbearable, for threshold and tolerance, respectively.

Intervention type: DEVICE
Intervention: Heat pain threshold and tolerance
Description: TSAII Neuroanalyzer (Medoc Advanced Medical Systems, Durham, NC), was used to assess the heat-related pain and tolerance of the volunteers defined as the respective temperatures where they started feeling as painful or unbearable.

Intervention type: PROCEDURE
Intervention: Polysomnography
Description: All volunteers underwent a polysomnography study at home or at Stanford Sleep Center, approximately one week before their experimental pain assessment in the laboratory
Study: NCT04652505

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study: NCT00201877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velcade
Description: Induction: 1.3 mg/m2 IV days 1 and 4 of weeks 1, 2, 4, 5, 7, 8, 10, 11, 13 \& 14.~Maintenance: 1.3 mg/m2 IV day 1 weekly x 2 weeks beginning week 20 and continuing every 6 months until month 23.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Induction: 375 mg/m2 IV day 1 of weeks 4, 5, 7, 8, 10, 11, 13 and 14 prior to Velcade administration.~Maintenance: 375 mg/m2 day 1 weekly x 4 weeks.
Study: NCT03420248

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-spherical polyvinyl alcohol particle or Tris-acryl gelatin microsphere
Description: One of non-spherical polyvinyl alcohol particle or tris-acryl gelatin microsphere is used for embolic materials. All other processes are same.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-spherical polyvinyl alcohol particle or Tris-acryl gelatin microsphere
Description: One of non-spherical polyvinyl alcohol particle or tris-acryl gelatin microsphere is used for embolic materials. All other processes are same.
Study: NCT01361542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti TNF alpha agent
Description: Anti TNF alpha therapy included either INFLIXIMAB or ETANERCEPY Infliximab at 3-5 mg/kg at recommended protocols for the duration of the study Etanercept at 50mg weekly for the duration of the study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti TNF alpha therapy
Description: Infliximab 3-5 mg/kg as per recommended protocol or Etanercept 50mg/week for 1 year
Study: NCT02573389

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Boston Scientific or Cook pancreatic duct stents
Description: Boston Scientific or Cook straight or pigtail pancreatic stents. Stent size depends on duct size (capacity). Pancreatic plastic stents are made primarily of polyethylene materials. Pancreatic stent sizes range from 2 to 25 cm in length and 3F to 11.5F in.
Study: NCT01260818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: 1 g Tranexamic Acid mixed with 100ml saline are kept in wound for 2 hours before drainage is opened postoperatively

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: 100ml saline is kept in wound for 2 hours before drainage is opened postoperatively
Study: NCT01734733

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NTCELL
Study: NCT02387268

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CleanC system
Description: Cleansing liquid and fecal matter during a standard colonoscopy procedure
Study: NCT00671177

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: water immersion colonoscopy
Description: instillation of 300cc of water in the rectum

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard air colonoscopy
Description: air instillation in colon for visualization
Study: NCT00781105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telbivudine
Description: 600 mg/day, oral tablets, once daily, 52 weeks
Study: NCT03990792

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: e-predictD intervention
Description: The intervention is based on validated risk algorithms to predict depression and includes: 1) Mobile applications as main user's interface; 2) a DSS that helps patients to develop their own personalized plans to prevent (PPP) depression; 3) eight intervention modules (the core of the system) including activities to prevent depression, to be proposed by the DSS and chosen by the patient. The intervention is biopsychosocial and multi-component, including the following modules: physical exercise, improving sleep, expanding relationships, problem solving, improving communication skills, assertiveness training, making decisions and managing thoughts. Patients will implement the recommendations and the tool will monitor these actions, offering feedback to improve their PPP at 3, 6 and 9 months. The intervention also includes an initial and single 15-minute face-to-face GP-patient interview.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brief psychoeducational intervention
Description: The intervention consists of an App that weekly send brief psychoeducational messages about physical and mental health (depression, anxiety, sleep hygiene, physical activity, etc.)
Study: NCT03780361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept Injection
Description: Total 5 times of monthly intravitreal aflibercept injections will be done.
Study: NCT00409721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Study: NCT02429453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Four Factor Prothrombin Complex Concentrate
Description: A purified, non-activated prothrombin complex concentrate containing factors II, VII, IX and X and proteins C \& S

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fresh Frozen Plasma
Description: A pooled collection of plasma from donors